Company intelligence / Profile preview

Huro Biotech

Ho Chi Minh City, Ho Chi Minh City, Vietnamhurobiotech.com ↗

Ownership: Private
Development stage: Other

Overview

Huro Biotech has commercial products (HURO BiO Probiotics, SPEROMED Nasal Spray) for digestive health and viral symptom relief. Its lead candidate, SPOR-COV®, is in Pre-clinical/Clinical tolerability studies in Vietnam with published animal/human data for flu/SARS-CoV‑2 symptom reduction, and planning for first human studies in Europe/USA.

Therapeutic areas: GastroenterologyOphthalmologyEndocrinologyDermatologyNeurologyInfectious Diseases
Modalities: Live biotherapeutic product therapy (probiotic spores)Postbiotic therapy (heat-inactivated spore-based ingredients)
Industry: Biotech

Drug pipeline

1 asset

Speromed

Unknown

Partnerships

SporeGen Biotechnology Company (UK)Destiny Pharma Pharmaceutical Company (UK)University of Liverpool academic collaborationRoyal Holloway University of London academic collaboration

Beyond the preview

Go deeper on Huro Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Huro Biotech.